Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

Investment Rating - The industry investment rating is "Positive" (首次) [1] Core Insights - The beauty and personal care industry is experiencing a mixed performance, with the beauty care index declining by 1.70% in December 2025, ranking 24th among all primary industries [15] - The medical beauty sector is seeing innovation with the approval of new products, such as the cross-linked recombinant collagen implant by Jiangsu Chuangjian Medical Technology Co., which is expected to inject new momentum into the market [7][34] - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, has successfully listed on the Hong Kong Stock Exchange, marking a significant milestone for domestic high-end skincare brands [8][39] Summary by Sections Market Review - In December, the beauty care index reported a decline of 1.70%, underperforming the broader market, which saw the Shanghai Composite Index increase by 2.06% [15] - For the entire year of 2025, the beauty care index showed a cumulative increase of 0.39%, again lagging behind the Shanghai Composite Index's 18.41% growth [15] Medical Beauty - Jiangsu Chuangjian Medical's cross-linked recombinant collagen implant has been approved, making it the fifth such product in China and the first cross-linked version [34] - The industry is shifting from single product competition to a full-chain layout, with companies like Jinjian Biological and Junzi Biological also making significant advancements in the recombinant collagen space [34][36] Cosmetics - Lin Qingxuan has established itself as a leader in the high-end domestic skincare market, achieving the highest retail sales among domestic brands in 2024 [39] - The company has built a comprehensive supply chain and employs an OMO (Online-Merge-Offline) model to enhance customer engagement and sales [39][49] - Lin Qingxuan's core product, the camellia oil essence, has a high repurchase rate of 33.5%, indicating strong customer loyalty [51] Investment Recommendations - The report recommends focusing on differentiated upstream medical beauty product manufacturers and chain medical beauty institutions, highlighting companies like Meili Tianyuan Medical Health and Aimeike [9][53] - In cosmetics, the report suggests investing in brands that innovate in emotional value and safe ingredients, with a focus on domestic brands like Maogeping and Lin Qingxuan [54]

Core Insights - The article emphasizes that despite the prevailing narrative of economic hardship, certain industries are thriving and generating substantial profits, particularly in Japan and China [3][4]. - It identifies eight key sectors that are capitalizing on changing consumer behaviors and preferences, suggesting that a low-desire society does not equate to a lack of opportunities [4][5]. Group 1: Key Industries - **Second-Hand Economy**: The second-hand luxury market in Japan, exemplified by companies like Daikokuya, has seen significant revenue growth. In China, platforms like Hongbulin and Panghu are experiencing similar success [6][7][8]. - **Pet Economy**: With a decline in birth rates, spending on pets has surged. Companies like Inaba in Japan and Guobao in China are benefiting from this trend, with various pet brands seeing continuous sales growth [12][13][14][15][16]. - **Adult Care**: The adult diaper market in Japan has surpassed $10 billion, indicating that aging populations can create substantial economic opportunities rather than being a burden [17][18][19]. - **Health Food and Beverages**: The rise in health consciousness has led to increased demand for products like sugar-free tea and functional beverages in both Japan and China, reflecting a broader trend in post-pandemic consumer behavior [21][22]. Group 2: Emerging Consumer Trends - **Beauty Economy**: Despite economic constraints, spending on beauty products like collagen supplements remains high, with brands like Weimei and U like achieving significant sales [23][24][25][26]. - **Outdoor Recreation**: Companies in the outdoor equipment sector, such as Snow Peak in Japan and various Chinese brands, are thriving as consumers seek outdoor experiences [29][30][31][32]. - **Convenience Economy**: The demand for convenience products, such as frozen foods and smart home appliances, is rising as younger generations prioritize time-saving solutions [39][40][42]. - **Lazy Economy**: The trend towards convenience is evident in the growth of products that save time, indicating that in a low-desire economy, time-saving may be more valuable than cost-saving [42][43][44].

Group 1 - The medical beauty sector increased by 2.39% on January 9, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] - Key stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 149.91, up 2.69%, and *ST Meigu closing at 3.34, down 1.18% [1] Group 2 - The medical beauty sector saw a net inflow of 192.35 million yuan from main funds, while retail investors experienced a net outflow of 3038.42 million yuan [1] - Specific stock fund flows indicated that Huaxi Biological had a main fund net inflow of 11.58 million yuan, while Ai Meike had a net outflow of 3941.60 million yuan from retail investors [2] - *ST Meigu had a significant net outflow of 1095.28 million yuan from main funds, but a net inflow of 956.07 million yuan from retail investors [2]

Group 1 - The medical beauty sector increased by 0.6% on January 8, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 4082.98, down 0.07%, while the Shenzhen Component Index closed at 13959.48, down 0.51% [1] - The trading volume and turnover for key stocks in the medical beauty sector were reported, with Huaxi Biological closing at 45.11, up 1.12% [1] Group 2 - The net inflow of main funds in the medical beauty sector was 21.5 million yuan, while retail funds experienced a net outflow of 16.96 million yuan [1] - Detailed fund flow data showed that Aimeike had a main fund net inflow of 15.25 million yuan, while Huaxi Biological had a net inflow of 13.26 million yuan [2] - ST Meigu experienced a significant net outflow of main funds at 7.01 million yuan, indicating a negative trend in investor sentiment [2]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

证券之星消息，1月7日医疗美容板块较上一交易日下跌0.74%，*ST美谷领跌。当日上证指数报收于 4085.77，上涨0.05%。深证成指报收于14030.56，上涨0.06%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出2679.3万元，游资资金净流入1374.35万元，散户 资金净流入1304.95万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资净流入 (元) 游资净占比 散户净流入 (元) 散户净占比 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 920982 锦波生物 | | | 2755.02万 | 12.55% | -1248.51万 | -5.69% | -439.98万 | -2.00% | | 688363 华熙生物 | | | 204.38万 | 1.30% | 771.92万 | 4. ...

证券之星消息，1月6日医疗美容板块较上一交易日上涨0.66%，爱美客领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 146.49 | 1.06% | 3.41万 | 4.98 乙 | | 688363 | 华熙生物 | 44.91 | 0.34% | 5.16万 | 2.31亿 | | 920982 | 锦波生物 | 236.12 | -0.22% | 7324.94 | 1.74亿 | | 000615 | *ST美谷 | 3.46 | -0.86% | 13.90万 | 4782.12万 | 从资金流向上来看，当日医疗美容板块主力资金净流出1283.62万元，游资资金净流入772.62万元，散户 资金净流入511.0万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | | | 主力净占比 游资净流入 ...

Investment Rating - The report indicates a positive outlook for the consumer service industry on the Beijing Stock Exchange, highlighting investment opportunities driven by policy support and emerging consumption trends [1][22]. Core Insights - The consumer market in China has shown signs of recovery, with the Consumer Price Index (CPI) reaching a year-high growth of 0.7% in November 2025, while the Producer Price Index (PPI) has shown marginal improvement [2][5]. - The report identifies several consumption hotspots, including policy-driven consumption, emotional economy, health consumption, silver economy, national trend economy, and experience economy [2][12]. - The median market capitalization growth for 41 consumer service companies on the Beijing Stock Exchange was +30.92% in 2025, with 36 companies (88%) experiencing an increase [13][15]. - The median Price-to-Earnings (PE) ratio for consumer service companies was reported at 46.3x, indicating relatively low valuations and potential investment opportunities in 2026 [19][22]. Summary by Sections Domestic Consumption Market Trends - In 2025, the CPI showed a gradual recovery, with November's growth at 0.7%, marking the highest point of the year [5]. - The retail sales growth varied across categories, with strong performance in communication equipment, home appliances, and furniture, while traditional consumer goods like tobacco, clothing, and beverages lagged [6][8]. Market Performance - The median market capitalization change for consumer service stocks was -2.39% in the last week of December 2025, with notable performers including Thunder God Technology (+10.10%) and Vision Intelligence (+3.14%) [12][15]. - The overall market capitalization for consumer service companies decreased from 115.18 billion to 109.71 billion yuan, with a median market cap drop from 1.906 billion to 1.873 billion yuan [12][15]. Valuation Metrics - The median PE ratio for the broader consumer industry was reported at 49.3x, reflecting a slight decrease from previous periods [19][22]. - Specific sectors such as food and beverage, and agriculture showed median PE ratios of 49.5x, indicating stable valuations despite market fluctuations [19][22]. Company Highlights - Key companies in the consumer service sector include Gai Shi Food, Oufu Egg Industry, and Biowave, with significant market capitalization growth and diverse product offerings [22][26]. - The report emphasizes the potential of companies in the pet food, cosmetics, and agricultural sectors, with a robust pipeline of companies poised for listing on the Beijing Stock Exchange [22][27].

证券之星消息，1月5日医疗美容板块较上一交易日上涨2.22%，华熙生物领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 44.76 | 2.47% | 4.79万 | 2.14亿 | | 300896 | 爱美客 | 144.95 | 2.28% | 3.97万 | 5.72亿 | | 920982 | 锦波生物 | 236.64 | 1.26% | 7690.59 | 1.80 Z | | 000615 | *ST美谷 | 3.49 | 0.00% | 11.32万 | 3982.21万 | 从资金流向上来看，当日医疗美容板块主力资金净流入1362.9万元，游资资金净流出704.42万元，散户资 金净流出658.47万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345 ...